Arbutus Biopharma (ABUS)
Develops chronic HBV therapies while monetizing legacy lipid-nanoparticle IP.
Something off on this page? Send us feedback.
Develops two chronic hepatitis B candidates, imdusiran and AB-101, in one reportable segment. The operating model is lean after restructuring and is shaped by legacy lipid-nanoparticle royalties, Genevant-linked settlements, and ongoing LNP patent litigation.
Develops chronic hepatitis B therapies around imdusiran, a subcutaneous GalNAc-conjugated RNAi candidate, and AB-101, an oral PD-L1 inhibitor. Imdusiran has FDA Fast Track designation, while AB-101 remains an early clinical program with a disclosed clinical-hold dependency.
Global imdusiran rights returned after the Greater China and Taiwan Qilu partnership ended, leaving a focused HBV portfolio under one reportable segment. Operations are lean after restructuring, with discovery work and in-house scientific research discontinued.
Legacy value is tied to lipid-nanoparticle intellectual property through Genevant, ONPATTRO royalty entitlements, the Moderna settlement, and ongoing Pfizer/BioNTech litigation. The business has no approved proprietary product sales in the context reviewed.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $92.6M · Total debt $3.6M · Total assets $274.0M · Shareholders' equity $258.7M
- Revenue
- $1.0M
- Operating income
- −$6.0M
- Net income
- −$5.1M
No dividends on record.
| Institutions | 71.79% | 142.04M shares | |
|---|---|---|---|
| 182 holders · as of Jun 30, 2026 | |||
| Insiders | 0.33% | 647.4K shares | |
| 5 holders · as of Feb 2, 2026 | |||
| Strategic holders | 19.64% | 38.85M shares | |
| 1 holder · as of Feb 25, 2025 | |||
| Other | 8.24% | 16.31M shares | |
| remainder | |||
197.85M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Roivant Sciences Ltd.1,2Strategic10 percent owner | 19.64% | 38.85M | filed Feb 25, 2025 |
Two Seas Capital LPInstitution | 9.65% | 19.10M | as of Jun 30, 2026 |
Morgan StanleyInstitution | 8.95% | 17.70M | as of Jun 30, 2026 |
Whitefort Capital Management, LPInstitution | 7.98% | 15.79M | as of Jun 30, 2026 |
Whitefort Capital Master Fund, LPInstitution | 7.98% | 15.79M | filed Sep 4, 2026 |
- Roivant Sciences Ltd.'s transaction reports restate only vehicles that traded; the 2025 ownership statement (38.85M) is used instead.
- Roivant Sciences Ltd. reports a block also reported by another filer; it is counted once, under that filer.
Insider tradesForm 4
No open-market trades in the last 12 months.
- GSK (ADR)
ASO-led HBV functional-cure challenger with an siRNA sequence regimen
- Gilead Sciences
Approved HBV antivirals and liver-disease scale set the incumbent bar
- Aligos Therapeutics
Oral capsid modulator program targets HBV suppression and antigens
- Assembly Biosciences
Next-generation HBV capsid modulator overlaps combination-cure work
- Precision BioSciences
Gene-editing HBV cure program targets cccDNA directly
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Arbutus Biopharma | $5.00 | +0.08% | $987.7M | 6.4 | — | 5.4 | −90.6% |
| GSK (ADR) | $50.79 | −0.57% | $102.34B | 16.1 | 9.3 | 2.3 | +5.3% |
| Gilead Sciences | $152.43 | +1.24% | $186.93B | — | 16.8 | 6.1 | +10.2% |
| Aligos Therapeutics | $6.00 | +9.22% | $34.0M | — | — | 1.1 | +2,778.6% |
| Assembly Biosciences | $25.72 | +1.10% | $504.2M | 46.3 | — | 6.7 | +38.9% |
| Precision BioSciences | $7.05 | +8.46% | $83.4M | — | — | 1.9 | −100.0% |
| Median | 31.2 | 13.0 | 2.3 | +10.2% |